More recently, the DAPA-CKD (Dapagliflozin andPrevention of Adverse Outcomes in Chronic Kidney Disease) trial included 4094patients, irrespective of diabetes status, who presented an eGFR between 25 and75 mL/min/1.73 m2 (CKD-EPI formula) and a urinary albumin-to-creatinineratio ≥200 mg/g. Here, ALB is linked to chronic kidney disease.